Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (190)	7/6/1998 10:19:00 PM
From: Frank Stein	Respond to of 579

found this at the Neuroinvestment website: neuroinv.com An alternate approach to ACh augmentation is to mimic the effect of ACh by using cholinergic receptor agonists. There are two subtypes of Ach receptors, muscarinic and nicotinic, and the two most advanced agonist-candidates are muscarinic; Novo Nordisk, Boehringer Ingelheim, and Parke-Davis have Phase III trials ongoing (with several others earlier in development). SIBIA has a nicotinic receptor agonist (SIB-1553) which reportedly boosts ACh levels by 25 times, compared to being roughly tripled by Aricept. SIB-1553 is a year away from human trials. For the most part, cholinergic strategies have been the province of Big Pharma, and reflects a Big Pharma lack of vision. While the particular potency of the SIBIA molecule is of interest, we see the cholinergic card as not having much 'upside potential', there is only so much boosting one can do of a dying system. However, given along with agents addressing the degenerative process itself, a potent ACh-enhancer would be far more appealing, because it could maximize the efficiency of a system that had been stabilized.